Tag:

Gilead Sciences

Latest Headlines

Latest Headlines

Gilead looks overseas to guard Sovaldi profits from taxes

Tax inversion deals are not the only trick Big Pharma has up its sleeve to avoid steep U.S. taxes. Gilead Sciences is booking profits overseas in low-tax countries to take home more profits for its blockbuster hep C drug Sovaldi.

Gilead's hep C star Harvoni, BMS' cancer med Opdivo lead ranks of 'exciting' launches

Which launches are the ones to watch? That can vary depending on who you're talking to. But as Bloomberg Intelligence recently found, industry members and healthcare investors have some similar ideas this year--and unsurprisingly, they've got their eyes on Gilead's Harvoni.

UPDATED: NIH funds studies of J&J's and GSK's injectable HIV meds, says daily pills lead to noncompliance

In bid to improve patient adherence, the U.S. National Institutes of Health is funding and helping run two clinical trials of long-acting injectable HIV candidates being developed by Johnson & Johnson's Janssen and GlaxoSmithKline.

Mylan bags rights to distribute Gilead's Sovaldi in India

Gilead has named Mylan as the exclusive distributor of branded forms of its hepatitis C blockbusters Sovaldi and Harvoni in India.

Gilead plows ahead in India with Mylan deal on hep C, but will it work?

Mylan Pharmaceuticals Private has signed an agreement with Gilead Sciences for exclusive rights in India to distribute the best-selling Sovaldi (sofosbuvir) and Harvoni combination with ledipasvir for treating hepatitis C.

UPDATE: Gilead hauled up over ADR reporting in Japan

Japan's Ministry of Health, Labor and Welfare (MHLW) scolded Gilead Sciences Inc. for its failure to report overseas adverse drug reaction (ADR) cases involving three drugs within the required timeframe.

Crown the new drug launch king: Gilead's Harvoni has knocked aside sister med Sovaldi

Move over, Sovaldi--there's a new launch king in town. And luckily for Gilead, it's another of its own. Harvoni has officially unseated its hep C predecessor, putting up $2.11 billion in revenue in its first quarter on the U.S. market. While that's less than Sovaldi recorded in Q1 of last year--it posted $2.27 billion in sales--Harvoni's Oct. 10 approval meant it missed two weeks of Q4 sales time.

Here's a switcheroo: HIV activists target Gilead for holding back on Truvada marketing

Gilead Sciences is no stranger to criticism. Consider the years-long outcry over HIV and hep C drug prices. But now the California-based company finds itself in a strange--yet somehow familiar--spotlight. At a time when the pharma industry is drawing fire for marketing its drugs to doctors, Gilead is drawing fire for not marketing enough.

How big are Gilead's hep C drug discounts? Enough to spook investors

Here's what a price war hath wrought. Gilead Sciences announced truly astounding 2014 results yesterday; sales more than doubled to $24.5 billion, thanks to its superstar hepatitis C pills Harvoni and Sovaldi. It's now a top 10 global drugmaker, sales-wise, bigger than Eli Lilly, likely bigger than Bayer Healthcare, and certainly bigger than its current hep C rival AbbVie.

FDA yanking 'breakthrough' bragging rights to Merck's hep C combo

Now that AbbVie has followed up on Gilead's game-changing combo with its own directly competitive hep C cocktail, Merck's late-stage player in the field doesn't look quite as revolutionary as it once did. With a new drug application being prepped for a near-term filing, the FDA has decided to drop its breakthrough therapy designation for Merck, possibly slowing the Big Pharma's marketing timeline a bit.